Many patients with high-risk myelodysplastic syndromes miss out on effective treatment, study finds
by american society of Hematology edited by Gaby Clark, reviewed by Robert Egan Credit: Unsplash/CC0 Public Domain Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The findings suggest that underuse of these drugs may help explain why MDS outcomes have not improved […]
